<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydroxyl (O) linked glycosylation defects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydroxyl (O) linked glycosylation defects</h1>
<div class="graphic"><div class="figure"><div class="ttl">Hydroxyl (O) linked glycosylation defects</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Gene</td> <td class="subtitle1_left">Gene locus MIM#</td> <td class="subtitle1_left">Function</td> <td class="subtitle1_left">Localization of defect</td> <td class="subtitle1_left">Disease</td> <td class="subtitle1_left">Inheritance</td> <td class="subtitle1_left">Initial molecular characterization (PMID)</td> </tr> <tr> <td class="subtitle2_left" colspan="7">O-mannosylation</td> </tr> <tr> <td class="indent1">Protein O-mannosyltransferase 1 (<em>POMT1</em>)</td> <td>607423</td> <td>Protein O-Man-transferase</td> <td>ER</td> <td>MDDGA1, MDDGB1, MDDGC1</td> <td>AR</td> <td>12369018</td> </tr> <tr> <td class="indent1">Protein O-mannosyltransferase 2 (<em>POMT2</em>)</td> <td>607439</td> <td>Protein O-Man-transferase</td> <td>ER</td> <td>MDDGA2, MDDGB2, MDDGC2</td> <td>AR</td> <td>15894594</td> </tr> <tr> <td class="indent1">Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) (<em>POMGNT1</em>)</td> <td>606822</td> <td>Beta 1-2 GlcNAc-transferase (transfers GlcNAc to mannose in core M1)</td> <td>Golgi</td> <td>MDDGA3, MDDGB3, MDDGC3, RP76</td> <td>AR</td> <td>11709191</td> </tr> <tr> <td class="indent1">Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) (<em>POMGNT2</em>)</td> <td>614828</td> <td>Beta 1-4 GlcNAc-transferase (transfers GlcNAc to mannose in core M3)</td> <td>ER</td> <td>MDDGA8</td> <td>AR</td> <td>22958903</td> </tr> <tr> <td class="indent1">Beta-1,3-N-acetylgalactosaminyltransferase 2 (<em>B3GALNT2</em>)</td> <td>610194</td> <td>Beta 1-3 GalNAc-transferase II (transfers GalNAc to GlcNAcMan in core M3)</td> <td>ER</td> <td>MDDGA11</td> <td>AR</td> <td>23453667</td> </tr> <tr> <td class="indent1">Protein O-mannose kinase (<em>POMK</em>)</td> <td>615247</td> <td>Phosphorylates 6-position of Man after addition of GlcNAc and GalNAc</td> <td>ER</td> <td>MDDGA12, MDDGC12</td> <td>AR</td> <td>23519211</td> </tr> <tr> <td class="indent1">CDP-L-ribitol pyrophosphorylase A (<em>CRPPA</em>)</td> <td>614631</td> <td>Synthesizes CDP-ribitol</td> <td>Cytosol</td> <td>MDDGA7, MDDGC7</td> <td>AR</td> <td>22522420, 22522421</td> </tr> <tr> <td class="indent1">Fukutin (<em>FKTN</em>)</td> <td>607440</td> <td>Adds ribitol-5-P to GalNAcGlcNAcMan6P</td> <td>Golgi</td> <td>MDDGA4, MDDGB4, MDDGC4</td> <td>AR</td> <td>9690476</td> </tr> <tr> <td class="indent1">Fukutin-related protein (<em>FKRP</em>)</td> <td>606596</td> <td>Adds ribitol-5-P to Rbo5PGalNAcGlcNAcMan6P</td> <td>Golgi</td> <td>MDDGA5, MDDGB5, MDDGC5</td> <td>AR</td> <td>11592034</td> </tr> <tr> <td class="indent1">Ribitol xylosyltransferase 1 (<em>RXYLT1</em>)</td> <td>605862</td> <td>Beta 1-4 xylosyltransferase (transfers xylose to Rbo5P Rbo5PGalNAcGlcNAcMan6P)</td> <td>Golgi</td> <td>MDDGA10</td> <td>AR</td> <td>23217329</td> </tr> <tr> <td class="indent1">Beta-1,4-glucuronyltransferase 1 (<em>B4GAT1</em>)</td> <td>605581</td> <td>Beta 1,4 glucuronyltransferase I (transfers GlcA to XylRbo5P Rbo5PGalNAcGlcNAcMan6P)</td> <td>Golgi</td> <td>MDDGA13</td> <td>AR</td> <td>23359570</td> </tr> <tr> <td class="indent1">LARGE xylosyl- and glucuronyltransferase 1 (<em>LARGE1</em>)</td> <td>603590</td> <td>Beta 1-3 GlcA-transferase/alpha 1-3 Xyl-transferase (transfers GlcAXyl to GlcAXylRbo5P Rbo5PGalNAcGlcNAcMan6P)</td> <td>Golgi</td> <td>MDDGA6, MDDGB6</td> <td>AR</td> <td>12966029</td> </tr> <tr> <td class="subtitle2_left" colspan="7">O-xylosylation</td> </tr> <tr> <td class="indent1">FAM20B glycosaminoglycan xylosylkinase (<em>FAM20B</em>)</td> <td>611063</td> <td>Glycosaminoglycan xylosylkinase</td> <td>Golgi</td> <td>FAM20B-CDG</td> <td>AR</td> <td>30847897</td> </tr> <tr> <td class="indent1">Xylosyltransferase 1 (<em>XYLT1</em>)</td> <td>608124</td> <td>Xyl-transferase 1</td> <td>Golgi</td> <td>Desbuquois dysplasia type 2</td> <td>AR</td> <td>23982343</td> </tr> <tr> <td class="indent1">Xylosyltransferase 2 (<em>XYLT2</em>)</td> <td>608125</td> <td>Xyl-transferase 2</td> <td>Golgi</td> <td>Spondyloocular syndrome</td> <td>AR</td> <td>26027496</td> </tr> <tr> <td class="indent1">Beta-1,4-galactosyltransferase 7 (<em>B4GALT7</em>)</td> <td>604327</td> <td>Beta 1-4 Gal-transferase I (transfers galactose to xylose)</td> <td>Golgi</td> <td>Progeroid EDS 1 (Larsen of Reunion Island syndrome)</td> <td>AR</td> <td>10473568, 10506123</td> </tr> <tr> <td class="indent1">Beta-1,3-galactosyltransferase 6 (<em>B3GALT6</em>)</td> <td>615291</td> <td>Beta 1-3 Gal-transferase II (transfers galactose to GalXyl)</td> <td>Golgi</td> <td>SEMDJL Beighton type (progeroid EDS type 2)</td> <td>AR</td> <td>23664117</td> </tr> <tr> <td class="indent1">Beta-1,3-glucuronyltransferase 3 (<em>B3GAT3</em>)</td> <td>606374</td> <td>Beta 1-3 GlcA-transferase I (transfers GlcA to GalGalXyl to create linker tetrasaccharide)</td> <td>Golgi</td> <td>Larsen-like syndrome</td> <td>AR</td> <td>21763480</td> </tr> <tr> <td class="indent1">Exostosin glycosyltransferase 1 (<em>EXT1</em>)</td> <td>608177</td> <td>Beta 1-4 GlcA-transferase II/alpha 1-4 GlcNAc-transferase II (HS polymerase)</td> <td>Golgi</td> <td>Multiple hereditary exostoses type 1</td> <td>AD</td> <td>7550340</td> </tr> <tr> <td class="indent1">Exostosin glycosyltransferase 2 (<em>EXT2</em>)</td> <td>608210</td> <td>Beta 1-4 GlcA-transferase II/alpha 1-4 GlcNAc-transferase II (HS polymerase)</td> <td>Golgi</td> <td>Multiple hereditary exostoses type 2; seizures, scoliosis and macrocephaly syndrome</td> <td>AD; AR</td> <td>8782816, 26246518</td> </tr> <tr> <td class="indent1">Exostosin-like glycosyltransferase 3 (<em>EXTL3</em>)</td> <td>605744</td> <td>Alpha 1-4 GlcNAc-transferase I (transfers first GlcNAc to linker for HS initiation) and II (HS elongation)</td> <td>Golgi</td> <td>Immunoskeletal dysplasia with neurodevelopmental abnormalities</td> <td>AR</td> <td>28132690, 28148688</td> </tr> <tr> <td class="indent1">N-deacetylase and N-sulfotransferase 1 (<em>NDST1</em>)</td> <td>600853</td> <td>N-deacetylates and N-sulfates GlcNAc in HS</td> <td>Golgi</td> <td>NDST1-CDG</td> <td>AR</td> <td>25125150</td> </tr> <tr> <td class="indent1">Heparan sulfate 6-O-sulfotransferase 1 (<em>HS6ST1</em>)</td> <td>604846</td> <td>Transfers sulfate to position 6 of GlcNAc in HS</td> <td>Golgi</td> <td>HS6ST1-CDG</td> <td>AD</td> <td>21700882</td> </tr> <tr> <td class="indent1">Heparan sulfate 6-O-sulfotransferase 2 (<em>HS6ST2</em>)</td> <td>300545</td> <td>Transfers sulfate to position 6 of GlcNAc in HS</td> <td>Golgi</td> <td>HS6ST2-CDG</td> <td>XL</td> <td>30471901</td> </tr> <tr> <td class="indent1">Chondroitin sulfate synthase 1 (<em>CHSY1</em>)</td> <td>608183</td> <td>Beta 1-3 GlcA-transferase/beta 1-4 GalNAc-transferase (CS elongation)</td> <td>Golgi</td> <td>Temtamy preaxial brachydactyly syndrome</td> <td>AR</td> <td>21129728</td> </tr> <tr> <td class="indent1">Carbohydrate sulfotransferase 3 (<em>CHST3</em>)</td> <td>603799</td> <td>GalNAc-6-O-sulfotransferase (CS modification)</td> <td>Golgi</td> <td>SED with congenital joint</td> <td>AR</td> <td>15215498</td> </tr> <tr> <td class="indent1">Carbohydrate sulfotransferase 14 (<em>CHST14</em>)</td> <td>608429</td> <td>GalNAc-4-O-sulfotransferase (DS modification)</td> <td>Golgi</td> <td>EDS musculocontractural type 1</td> <td>AR</td> <td>20004762</td> </tr> <tr> <td class="indent1">Dermatan sulfate epimerase (<em>DSE</em>)</td> <td>605942</td> <td>Converts D-glucuronic acid to L-iduronic acid (DS epimerase)</td> <td>Golgi</td> <td>EDS musculocontractural type 2</td> <td>AR</td> <td>23704329</td> </tr> <tr> <td class="indent1">Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (<em>CSGALNACT1</em>)</td> <td>616615</td> <td>Beta 1-4 GalNAc-transferase I (transfers first GalNAc to linker for CS initiation)</td> <td>Golgi</td> <td>Desbuquois dysplasia</td> <td>AR</td> <td>27599773</td> </tr> <tr> <td class="indent1">Carbohydrate sulfotransferase 6 (<em>CHST6</em>)</td> <td>605294</td> <td>GlcNAc-6-O-sulfotransferase (KS modification)</td> <td>Golgi</td> <td>Macular corneal dystrophy</td> <td>AR</td> <td>11017086</td> </tr> <tr> <td class="indent1">Calcium-activated nucleotidase 1 (<em>CANT1</em>)</td> <td>613165</td> <td>UDP-Gal nucleotidase</td> <td>ER and Golgi</td> <td>Desbuquois dysplasia 1</td> <td>AR</td> <td>19853239</td> </tr> <tr> <td class="subtitle2_left" colspan="7">O-GalNAcylation</td> </tr> <tr> <td class="indent1">Polypeptide N-acetylgalactosaminyltransferase 3 (<em>GALNT3</em>)</td> <td>601756</td> <td>Polypeptide GalNAc-transferase</td> <td>Golgi</td> <td>Hyperphosphatemic familial tumoral calcinosis</td> <td>AR</td> <td>15133511</td> </tr> <tr> <td class="indent1">Polypeptide N-acetylgalactosaminyltransferase 14 (<em>GALNT14</em>)</td> <td>608225</td> <td>Polypeptide GalNAc-transferase</td> <td>Golgi</td> <td>GALNT14-CDG</td> <td>AR</td> <td>26036949</td> </tr> <tr> <td class="indent1">C1GALT1-specific chaperone 1 (<em>C1GALT1C1</em>)</td> <td>300611</td> <td>Chaperone for the core 1 beta 1-3 galactosyltransferase</td> <td>ER</td> <td>Tn polyagglutination syndrome</td> <td>Somatic</td> <td>16251947</td> </tr> <tr> <td class="indent1">O-linked GlcNAc transferase (<em>OGT</em>)</td> <td>300255</td> <td>O-GlcNAc transferase</td> <td>Nucleus and cytosol</td> <td>MRX106</td> <td>XL</td> <td>28302723, 28584052, 32080367</td> </tr> <tr> <td class="indent1">EGF domain-specific O-linked GlcNAc transferase (<em>EOGT</em>)</td> <td>614789</td> <td>EGF-domain O-GlcNAc transferase</td> <td>ER</td> <td>Adams-Oliver syndrome 4</td> <td>AR</td> <td>23522784</td> </tr> <tr> <td class="indent1">ST3 beta-galactoside alpha-2,3-sialyltransferase 3 (<em>ST3GAL3</em>)</td> <td>606494</td> <td>Alpha 2-3 sialyltransferase (transfers sialyl to Lewis alpha trisaccharide)</td> <td>Golgi</td> <td>MRT12; EIEE15</td> <td>AR</td> <td>21907012, 23252400</td> </tr> <tr> <td class="subtitle2_left" colspan="7">O-glycosylation</td> </tr> <tr> <td class="indent1">Protein O-glucosyltransferase 1 (<em>POGLUT1</em>)</td> <td>615618</td> <td>Protein O-glucosyltransferase</td> <td>ER</td> <td>Dowling-Degos disease 4; LGMD2Z</td> <td>AD; AR</td> <td>24387993, 27807076</td> </tr> <tr> <td class="subtitle2_left" colspan="7">O-fucosylation</td> </tr> <tr> <td class="indent1">Protein O-fucosyltransferase 1 (<em>POFUT1</em>)</td> <td>607491</td> <td>Protein O-fucosyltransferase for EGF repeats</td> <td>ER</td> <td>Dowling-Degos disease 2</td> <td>AD</td> <td>23684010</td> </tr> <tr> <td class="indent1">LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase (<em>LFNG</em>)</td> <td>602576</td> <td>Beta 1-3 GlcNAc-transferase (transfers GlcNAc to O-fucose on EGF repeats)</td> <td>Golgi</td> <td>Spondylocostal dysostosis type 3</td> <td>AR</td> <td>16385447</td> </tr> <tr> <td class="indent1">Beta 3-glucosyltransferase (<em>B3GLCT</em>)</td> <td>610308</td> <td>Beta 1-3 Glc-transferase (transfers Glc to O-fucose on TSR)</td> <td>ER</td> <td>Peters-Plus syndrome</td> <td>AR</td> <td>16909395</td> </tr> </tbody></table></div><div class="graphic_footnotes">ER: endoplasmic reticulum; MDDG: muscular dystrophy-dystroglycanopathy; AR: autosomal recessive; GlcNAc: N-acetylglucosamine; RP: retinitis pigmentosa; GalNAc: N-acetylgalactosamine; Man6P: mannose 6-phoshate; CDG: congenital disorder of glycosylation; EDS: Ehlers-Danlos syndrome; SEMDJL: spondyloepimetaphyseal dysplasia with joint laxity; HS: heparan sulfate; AD: autosomal dominant; XL: X linked; CS: chondroitin sulfate; SED: spondyloepiphyseal dysplasia; DS: dermatan sulfate; KS: keratan sulfate; MRX: intellectual disability, X linked; EGF: epidermal growth factor; MRT: intellectual disability; EIEE: early infantile epileptic encephalopathy; LGMD: limb-girdle muscular dystrophy; TSR: thrombospondin type 1 repeats.</div><div class="graphic_reference">Adapted from: Ferreira CR, Altassan R, Marques-Da-Silva D, et al. Recognizable phenotypes in CDG. J Inherit Metab Dis 2018; 41:541.</div><div id="graphicVersion">Graphic 140152 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
